Abstract: Methods and compositions using an inhibitor of EGFR signaling for prevention or an inhibitor of EGFR signaling and a nucleic acid molecule encoding an atonal-associated factor for treatment of hearing loss are described.

Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

Abstract: Provided is an acetic acid production method that enables smooth reduction and/or increase of acetic acid production with easy operation and can industrially efficiently, stably produce acetic acid with maintained quality even when the acetic acid production volume is changed. The acetic acid production method includes a carbonylation step in which methanol is reacted with carbon monoxide in a continuous system in the presence of a catalytic system, acetic acid, methyl acetate, and water, where the catalytic system includes a metal catalyst and methyl iodide. The carbonylation step employs two or more reactors disposed in parallel.

Abstract: Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-heteroaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribavirin, and the like.

Abstract: The invention relates to a method for preparation of (meth)acrylic acid esters from (meth)acrylic acid anhydrides. The method involves: reacting a (meth)acrylic acid anhydride of Formula (I): wherein R1 is a hydrogen atom or a methyl group; with a substrate in the presence of a first catalyst to form a product mixture comprising the (meth)acrylic acid ester; and wherein: the substrate is selected from the group consisting of: primary alcohols; secondary alcohols; tertiary alcohols; and phenols; and the first catalyst comprises a salt of magnesium or of a rare earth element.

Abstract: A method of producing an organic peroxide includes introducing an organic solution and a peroxide solution into a mixing tank to form a mixture. The method further includes circulating the mixture over a fixed catalyst bed to form the organic peroxide and measuring a concentration of the organic peroxide in the mixture. Further, the method includes removing at least a portion of the mixture when the concentration reaches a set value.

Abstract: A method for preparing a low migration plasticizer of di-2-ethylhexyl terephthalate is provided. The method includes a step of adding a short chain alcohol component having 4 to 6 carbon atoms and a long chain alcohol component having 9 to 13 carbon atoms in an esterification reaction between terephthalic acid and 2-ethylhexanol, so as to obtain a modified di-2-ethylhexyl terephthalate including residues derived from the short chain alcohol component and the long chain alcohol component. The esterification reaction is carried out under a temperature from 30° C. to 225° C. and a pressure from 80 mbar to 1033 mbar.

Abstract: The present disclosure relates to methods of treating a malignancy in a subject in need thereof. The method involves administering to the subject a combination therapy comprising: (i) an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, polymorph, or solvates thereof, and (ii) an inhibitor of an anti-apoptotic Bcl-2 family protein, where the combination therapy is administered in an amount effective to treat the malignancy in the subject. Also disclosed are methods of reducing levels of regulatory T cells in a patient suffering from a malignancy, as well as combination therapeutics comprising an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein (MALT1) having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, polymorph, or solvates thereof, and an inhibitor of an anti-apoptotic Bcl-2 family protein.

Abstract: A process for producing methacrylic acid or a methacrylic acid ester including, producing acrolein, reacting the produced acrolein with hydrogen to produce propanal, reacting the propanal with formaldehyde to produce methacrolein, and oxidizing the methacrolein in the presence of an oxygen containing gas and optionally an alcohol, to methacrylic acid or a methacrylic acid ester.

Abstract: A material for lithography containing a tellurium-containing compound or a tellurium-containing resin, a production method therefor, a composition for lithography, a pattern formation method, a compound, a resin, and a method for purifying the compound or the resin are provided. The compounds and materials can provide for high solubility in a safe solvent.

Abstract: A process prepares dialkyl 1,4-cyclohexanedicarboxylates by ring hydrogenation of the corresponding dialkyl terephthalate having a CO value of less than 0.3 mg KOH/g. The dialkyl 1,4-cyclohexanedicarboxylates thus produced can be used as plasticizers or as a component of a plasticizer composition for plastics, in particular PVC.

Abstract: The present invention describes methods of identifying drugs for the treatment or prevention of diabetes by measuring the activity of the human zinc transporter ZnT8 and pharmaceutical compositions.

Abstract: The invention provides a method for treating cancer in which a level of reduced folate carrier (RFC) or folylpolyglutamate synthetase (FPGS) in cancer cells of the biopsy is determined. If the level of RFC or FPGS in the cancer cells is below a threshold value, the cancer is treated with an inhibitor of serine-hydroxymethyl-transferase (SHMT)1. If the level of RFC or FPGS in the cancer cells is above the threshold value, the cancer is treated with an inhibitor of SHMT2.

Abstract: An object of the present invention is to provide a method for producing a fluorinated organic compound, whereby an iodosylbenzene derivative can be easily separated and recovered.

Abstract: The present invention relates to an injectable composition of testosterone ester for the treatment of testosterone deficiency. Particularly, the present invention relates to a pharmaceutical composition comprising testosterone undecanoate, which is capable of increasing the convenience for use in injection with the low viscosity and injection force, and has improved stability.

Abstract: The present disclosure provides improved methods of performing ozonolysis on alkenes comprising non-reductive quenching of ozonide intermediates using Bronsted bases to yield aldehyde, ketone and/or carboxylic acid products.

Abstract: The present disclosure discloses salts formed by 2-(1-acyloxy-n-pentyl)benzoic acid and basic amino acid or aminoguanidine, a preparation method thereof, pharmaceutical preparations containing these salts, and application thereof in preparation of drugs for preventing or treating ischemic cardiovascular and cerebrovascular diseases, resisting thrombosis and improving cardio-cerebral circulation disorders. The compound of the present disclosure has excellent water solubility, aqueous solution stability and pharmacokinetic properties, also has significant anti-platelet aggregation, anti-thrombosis, anti-cerebral ischemia and neuroprotective activity.

Abstract: The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.

Abstract: Methods and systems for producing acetic acid, including glacial acetic acid. A first stream of a reactor fluid that includes methyl acetate, water, and a first amount of carbon monoxide may be forwarded from a reactor to a reactor cooler to form a cooled reactor fluid. The cooled reactor fluid may have a concentration of methyl acetate that is lower than the concentration of methyl acetate in the reactor fluid.

Abstract: The present invention provides a process for preparing 6-isopropenyl-3-methyl-9-decenyl acetate (5): wherein Ac represents an acetyl group, the process comprising steps of: subjecting a 2-methyl-2,6-heptadiene compound (1) having a leaving group X at position 1: wherein X represents an acyloxy group having 1 to 10 carbon atoms including the carbon atom of the carbonyl group, an alkanesulfonyloxy group having 1 to 10 carbon atoms, an arenesulfonyloxy group having 6 to 20 carbon atoms, or a halogen atom, to a nucleophilic substitution reaction with a 3-methylpentyl nucleophilic reagent (2) having a protected hydroxyl group at position 5: wherein M represents Li, MgZ1, ZnZ1, Cu, CuZ1, or CuLiZ1, wherein Z1 represents a halogen atom or a CH2CH2CH(CH3)CH2CH2OR group, and R represents a protecting group for a hydroxyl group, to form a 6-isopropenyl-3-methyl-9-decene compound (3) having a protected hydroxyl group at position 1: wherein R is as defined above; subjecting the 6-isopropenyl-3-methyl-9-decene compound (3